A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Conditions
- Multiple Myeloma
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma
Interventions
- DRUG: Elranatamab
- BIOLOGICAL: GM-CSF
- BIOLOGICAL: DC/MM Fusion Vaccine
Sponsor
David Avigan
Collaborators